Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00897676 · ClinicalTrials.gov registry record · Phase 1
Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity
A Phase 1 study of Congenital Hyperinsulinism, sponsored by Diva De Leon.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT00897676 is a Phase 1 study of Congenital Hyperinsulinism that has completed, run by Diva De Leon. The registered enrollment target is 17 participants, below the 76-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00897676, a Phase 1 study of Congenital Hyperinsulinism, has completed, sponsored by Diva De Leon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of exendin-(9-39) on fasting blood glucose and protein induced hypoglycemia on subjects with Congenital Hyperinsulinism. Funding Source - FDA Office of Orphan Products Development (OODP).
Conditions Studied
Interventions
- DRUG placebo
- DRUG Exendin-(9-39)
Study Locations (1)
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-05 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00897676
The ClinicalTrials.gov registry entry for NCT00897676 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (78% lower). The listed sponsor is Diva De Leon, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Hyperinsulinism appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00897676 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00897676 about?
NCT00897676 is a clinical study titled "Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity". The purpose of this study is to examine the effects of exendin-(9-39) on fasting blood glucose and protein induced hypoglycemia on subjects with Congenital Hyperinsulinism. Funding Source - FDA Office of Orphan Products Development (OODP).
What is the current status of trial NCT00897676?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-05. Estimated completion is 2017-01.
What conditions does trial NCT00897676 study?
This clinical trial studies the following conditions: Congenital Hyperinsulinism.
What interventions are being tested in trial NCT00897676?
The interventions under investigation include: placebo (DRUG), Exendin-(9-39) (DRUG).
Who is sponsoring clinical trial NCT00897676?
This trial is sponsored by Diva De Leon, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00897676 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Hyperinsulinism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
RECRUITING · Phase 1
-
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
RECRUITING · Phase 2
-
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
RECRUITING · Phase 2
-
RZ358 Treatment for Congenital Hyperinsulinism
ACTIVE NOT RECRUITING · Phase 3
-
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
ACTIVE NOT RECRUITING · Phase 3
-
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.